71 patents
Utility
Combination of Vaccination and Inhibition of the PD-1 Pathway
25 May 23
The present invention relates to a vaccine/inhibitor combination comprising an RNA vaccine comprising at least one RNA comprising at least one open reading frame (ORF) coding for at least one antigen and a composition comprising at least one PD-1 pathway inhibitor, preferably directed against PD-1 receptor or its ligands PD-L1 and PD-L2.
Mariola FOTIN-MLECZEK, Karl-Josef KALLEN, Jochen PROBST
Filed: 24 Aug 22
Utility
Rotavirus Vaccines
27 Apr 23
The present invention provides mRNA sequences comprising at least one coding region, encoding for at least one epitope of a protein, or of a fragment, variant or derivative thereof, of a virus of the genus rotavirus.
Susanne RAUCH, Benjamin PETSCH
Filed: 7 Jul 22
Utility
Lipid Nanoparticles for Delivery of Nucleic Acids
23 Mar 23
The application relates to cationic lipids and to compositions comprising said cationic lipids useful for the delivery of nucleic acids into living cells.
Gemma NAVARRO, Patrick BAUMHOF
Filed: 18 Dec 20
Utility
NUCLEIC ACIDS COMPRISING FORMULA (NuGlXmGnNv)a AND DERIVATIVES THEREOF AS IMMUNOSTIMULATING AGENT/ADJUVANT
22 Dec 22
The present invention relates to nucleic acids of the general formula (I): (NuGlXmGnNv)a and derivatives thereof as an immunostimulating agent/adjuvant and to compositions containing same, optionally comprising an additional adjuvant.
Thomas KRAMPS, Söhnke VOSS, Jochen PROBST, Ingmar HOERR
Filed: 29 Jun 22
Utility
Coronavirus Vaccine
15 Dec 22
The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19.
Susanne RAUCH, Hans Wolfgang GROßE, Benjamin PETSCH
Filed: 9 Aug 22
Utility
Rna for Cancer Therapy
15 Dec 22
The present invention relates to RNA, particularly an immunostimulatory RNA (isRNA), a coding RNA or a combination thereof, for use in the treatment or prophylaxis of a disease, in particular a tumor and/or cancer disease.
Mariola FOTIN-MLECZEK, Aleksandra KOWALCZYK, Regina HEIDENREICH, Ulrike GNAD-VOGT, Ute KLINKHARDT, Katja FIEDLER
Filed: 10 Jan 22
Utility
Dry Powder Composition Comprising Long-chain Rna
8 Dec 22
The present invention is directed to a storage-stable formulation of long-chain RNA.
Fabian Johannes EBER, Benyamin YAZDAN PANAH, Stefanie SEWING, Thomas KETTERER, Thorsten MUTZKE, Tilmann ROOS, Michael SONNTAG, Michael WIGGENHORN, Katharina KOLLAND
Filed: 11 Jul 22
Utility
Method for In Vitro Transcription Using an Immobilized Restriction Enzyme
8 Dec 22
The present invention relates to a method for in vitro transcription of a linear template DNA which is produced using an immobilized restriction endonuclease.
Tilmann ROOS, Benyamin YAZDAN PANAH, Martin KUNZE
Filed: 17 Aug 22
Utility
Rna-coded Antibody
24 Nov 22
The present application describes an antibody-coding, non-modified or modified RNA and the use thereof for expression of this antibody, for the preparation of a pharmaceutical composition, in particular a passive vaccine, for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, autoimmune diseases, virus diseases and monogenetic diseases, e.g. also in gene therapy.
Ingmar HOERR, Jochen PROBST, Steve PASCOLO
Filed: 19 Jul 22
Utility
Immobilized Poly(n)polymerase
3 Nov 22
The present invention relates to an immobilized poly(N)polymerase (PNP), methods of producing said PNP and uses thereof.
Tilmann ROOS, Benyamin YAZDAN PANAH, Markus CONZELMANN, Veronika WAGNER
Filed: 13 Jun 22
Utility
Kras Variant Mrna Molecules
27 Oct 22
The present invention provides an mRNA molecule encoding at least one KRAS variant peptide.
Amit AGGARWAL, Katja FIEDLER, Ulrike GNAD-VOGT, Regina HEIDENREICH, Mythili KONERU, Gregory D. PLOWMAN
Filed: 6 Dec 19
Utility
RNA vaccine against SARS-CoV-2 variants
20 Oct 22
The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19.
Nicole ROTH, Diego Chaves MORENO, Hans Wolfgang GROßE, Dominik VAHRENHORST, Susanne RAUCH
Filed: 31 May 22
Utility
Rotavirus Mrna Vaccine
6 Oct 22
The invention is directed to a coding RNA for a Rotavirus vaccine.
Susanne RAUCH, Sandro ROIER, Benjamin PETSCH
Filed: 18 Jun 20
Utility
Artificial Nucleic Acid Molecules for Improved Protein Expression
29 Sep 22
The invention relates to an artificial nucleic acid molecule comprising an open reading frame and a 3′-UTR comprising at least one poly(A) sequence or a polyadenylation signal.
Andreas THESS, Thomas SCHLAKE, Stefanie GRUND
Filed: 5 Apr 22
Utility
Rna Combinations and Compositions with Decreased Immunostimulatory Properties
22 Sep 22
The invention relates inter alia to a combination comprising (i) a first component comprising at least one therapeutic RNA and (ii) a second component comprising at least one antagonist of at least one RNA sensing pattern recognition receptor.
Andreas THESS, Frédéric CHEVESSIER-TÜNNESEN, Johannes LUTZ, Thomas SCHLAKE
Filed: 11 Aug 20
Utility
Rabies Vaccine
15 Sep 22
Margit SCHNEE, Thomas KRAMPS, Lothar STITZ, Benjamin PETSCH
Filed: 17 May 22
Utility
Method for Purifying Rna
15 Sep 22
The present invention relates to methods for purifying RNA by chromatography under high salt conditions, e.g. by hydrophobic interaction chromatography.
Andreas FUNKNER, Stefanie SEWING, Isabel STROBEL, Thorsten MUTZKE
Filed: 9 Feb 22
Utility
Nucleic Acid Based Combination Vaccines
11 Aug 22
The present invention is inter alia directed to pharmaceutical compositions comprising at least one nucleic acid encoding at least one antigenic peptide or protein from a Coronavirus, preferably a pandemic Coronavirus, and at least one nucleic acid encoding at least one antigenic peptide or protein from a further virus, e.g. an Influenza virus or an RSV virus.
Cornelia OOSTVOGELS, Benjamin PETSCH, Susanne RAUCH, Kim Ellen SCHWENDT
Filed: 7 Feb 22
Utility
Novel Artificial Nucleic Acid Molecules
28 Jul 22
The present invention provides artificial nucleic acid molecules comprising novel combinations of 5′ and 3′ untranslated region (UTR) elements.
Thomas SCHLAKE, Andreas THESS, Moritz THRAN, Frédéric CHEVESSIER-TÜNNESEN, Marion PÖNISCH
Filed: 17 Oct 18
Utility
Coronavirus Vaccine
14 Jul 22
The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19.
Susanne RAUCH, Hans Wolfgang GROßE, Benjamin PETSCH
Filed: 15 Nov 21